Aktuellt
SENASTE
Redeye comments on InDex Pharmaceuticals following its Q1 2023 report. We consider the report undramatic and do not make any significant adjustments. Again, we highlight that InDex trades at a notable discount compared to its cash position.
LÄS MER
